4D Molecular Therapeutics (FDMT) Current Leases (2021 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Current Leases of $5.5 million for Q1 2026, down 3.4% year-over-year from $5.7 million in Q1 2025, and down 1.9% quarter-over-quarter from $5.6 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Current Leases (2021 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Current Leases for 6 consecutive years, with $5.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Leases fell 3.4% year-over-year to $5.5 million; the TTM figure through Mar 2026 stood at $5.5 million (down 3.4% YoY), while the FY2025 annual figure was $5.6 million, down 0.8% from the prior year.
- Current Leases slipped to $5.5 million in Q1 2026 per FDMT's latest filing, from $5.6 million in the prior quarter.
- Across five years, Current Leases topped out at $5.7 million in Q2 2025 and bottomed at $2.0 million in Q1 2022.
- Historically, Current Leases has averaged $4.0 million across 5 years, with a median of $3.2 million in 2024.
- Annual changes were most pronounced in 2022 — Current Leases jumped 115.68% — and 2026, when it slipped 3.4%.
- 4D Molecular Therapeutics' Current Leases stood at $2.7 million in 2022, then grew by 18.61% to $3.1 million in 2023, then surged by 79.01% to $5.6 million in 2024, then slipped by 0.8% to $5.6 million in 2025, then slipped by 1.9% to $5.5 million in 2026.
- Business Quant data shows FDMT's Current Leases at $5.5 million in Q1 2026, $5.6 million in Q4 2025, and $5.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | 5.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.37 Mn |
| Mar 31, 2026 | 5.49 Mn |
| Dec 31, 2025 | 5.59 Mn |
| Sep 30, 2025 | 5.70 Mn |
| Jun 30, 2025 | 5.72 Mn |
| Mar 31, 2025 | 5.68 Mn |
| Dec 31, 2024 | 5.64 Mn |
| Sep 30, 2024 | 5.09 Mn |
| Jun 30, 2024 | 3.20 Mn |
| Mar 31, 2024 | 3.17 Mn |
| Dec 31, 2023 | 3.15 Mn |
| Sep 30, 2023 | 3.13 Mn |
| Jun 30, 2023 | 3.10 Mn |
| Mar 31, 2023 | 2.68 Mn |
| Dec 31, 2022 | 2.66 Mn |
| Sep 30, 2022 | 2.63 Mn |
| Jun 30, 2022 | 2.60 Mn |
| Mar 31, 2022 | 2.04 Mn |
| Dec 31, 2021 | 1.23 Mn |